A Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye
Phase of Trial: Phase III
Latest Information Update: 20 Dec 2017
Price : $35 *
At a glance
- Drugs PRO 148 (Primary) ; Polyethylene glycols; Propylene glycol
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Laboratorios Sophia
- 19 May 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 May 2014 Planned end date changed from 1 May 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 11 Apr 2014 New trial record